Table 2. Summary of correlation between hypermethylation of Wnt inhibitors and clinical and laboratory features.
| Variables a | Wnt b | SFRP c | SFRP1 | SFRP2 | SFRP5 | DKK1 | Wif1 |
|---|---|---|---|---|---|---|---|
| Genderd | +(0.023) | ||||||
| M0 | +(0.0254) | +(0.0079) | +(0.0008) | +(0.0104) | |||
| M1 | +(0.0035) | ||||||
| M2 | +(0.0114) | ||||||
| M3 | −(0.0298) | +(0.0005) | |||||
| M4/M5 | −(0.0006) | −(0.0009) | −(0.0083) | −(0.0019) | |||
| WBCd | −(<0.0001) | −(<0.0001) | −(<0.0001) | −(<0.0001) | −(0.0086) | −(0.0006) | −(0.0128) |
| Blastd | −(<0.0001) | −(0.0002) | −(0.0029) | −(0.0072) | −(0.0053) | −(0.045) | |
| Pltd | +(0.0144) | ||||||
| LDHd | −(0.0003) | −(0.0004) | −(0.0443) | −(0.0196) |
Abbreviations: blank=no significant association; LDH=lactate dehydrogenase; plt=platelet; +=positive association (P-value); −=negative association (P-value).
a
No significant correlation of hypermethylation of Wnt inhibitors with age and haemoglobin level, which were not shown in this table.
b
Hypermethylation of any Wnt inhibitors including SFRP, Wif-1, and DKK1.
c
Hypermethylation of any SFRP gene including SFRP1, SFRP2, SFRP4, and SFRP5.
d
Gender (correlation with male); white blood cells, blast, platelet, and LDH (correlation with high level).